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Abstract
In contrast to many years of important research and clinical attention to the pathological effects of
alcohol (ethanol) abuse, the past several decades have seen the publication of a number of peer-
reviewed studies indicating beneficial effects of light-moderate, non-binge consumption of varied
alcoholic beverages, as well as experimental demonstrations that moderate alcohol exposure can
initiate typically cytoprotective mechanisms. A considerable body of epidemiology associates
moderate alcohol consumption with significantly reduced risks of coronary heart disease and,
albeit currently a less robust relationship, cerebrovascular (ischemic) stroke. Experimental studies
with experimental rodent models and cultures (cardiac myocytes, endothelial cells) indicate that
moderate alcohol exposure can promote anti-inflammatory processes involving adenosine
receptors, protein kinase C (PKC), nitric oxide synthase, heat shock proteins, and others which
could underlie cardioprotection. Also, brain functional comparisons between older moderate
alcohol consumers and non-drinkers have received more recent epidemiological study. In over half
of nearly 45 reports since the early 1990’s, significantly reduced risks of cognitive loss or
dementia in moderate, non-binge consumers of alcohol (wine, beer, liquor) have been observed,
whereas increased risk has been seen in only a few studies. Physiological explanations for the
apparent CNS benefits of moderate consumption have invoked alcohol’s cardiovascular and/or
hematological effects, but there is also experimental evidence that moderate alcohol levels can
exert direct “neuroprotective” actions—pertinent are several studies in vivo and rat brain
organotypic cultures, in which antecedent or preconditioning exposure to moderate alcohol
neuroprotects against ischemia, endotoxin, β-amyloid, a toxic protein intimately associated with
Alzheimer’s, or gp120, the neuroinflammatory HIV-1 envelope protein. The alcohol-dependent
neuroprotected state appears linked to activation of signal transduction processes potentially
involving reactive oxygen species, several key protein kinases, and increased heat shock proteins.
Thus to a certain extent, moderate alcohol exposure appears to trigger analogous mild stress-
associated, anti-inflammatory mechanisms in the heart, vasculature and brain that tend to promote
cellular survival pathways.
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Introduction
This minireview derived from an RSA roundtable coalesces emerging information about the
epidemiology of heart disease, stroke and dementia in moderate, non-binge alcohol (ethanol)
consumers with relatively recent results of laboratory studies of biochemical and
physiological mechanisms that potentially underlie observed cytoprotective actions of
moderate alcohol concentrations. The pathological damage and vast social havoc from
addiction to and abuse of alcohol are well-known, and of necessity should continue to
receive primary attention by doctors, scientific researchers and health professionals.
However, results from human moderate consumption studies indicate that light-to-moderate,
responsible alcohol consumption appears to carry certain health benefits.
Most of the epidemiological evidence for cytoprotection relates to the heart and vasculature.
Experimentally, ischemia-reperfusion studies with cardiac myocytes and chronic alcohol-
consuming mice have shown that moderate alcohol-dependent cardioprotection is linked to
selective activation of protein kinase C (esp. PKCε isoform) and preservation of
mitochondrial function. Furthermore, low-dose alcohol consumption in ischemic rats
improves ventricular function while inducing cardioprotective proteins, e.g., heat shock
proteins, superoxide dismutase, and nitric oxide synthase (NOS). When present in alcoholic
beverages, the flavonoid resveratrol may play an important augmenting or independent role.
Further studies also confirm that the endothelium is critical in moderate alcohol-dependent
cardiovascular protection through changes in NOS as well as enhanced pro-fibrinolytic
enzymes. Additionally, antecedent alcohol ingestion in an ischemia-reperfusion rat model
has been shown to trigger entry of the microvasculature into a preconditioned, protected
state that involves adenosine receptors, NOS, calcitonin gene-related peptide release and at
least one heat shock protein, heme oxygenase.
Turning to the CNS, in the past decade or so a number of peer-reviewed cohort studies have
reported significantly reduced risks of either cognitive decline or dementia, including
Alzheimer’s, in light-moderate alcoholic beverage consumers in comparison to nondrinkers
or never-drinkers. Although some of the vascular and hematological mechanisms triggered
by moderate alcohol could favorably impact the aging brain, other more central brain
molecular pathways possibly triggered by episodic low/moderate levels of alcohol that could
exert anti-neuroinflammatory effects are possible contributors to neuroprotection.
MODERATE ALCOHOL CONSUMPTION AND RISK OF CORONARY
DISEASE, STROKE AND DEMENTIA: AN EPIDEMIOLOGICAL OVERVIEW
The observed associations of alcohol consumed within recommended guidelines with a
variety of chronic diseases at the population level continue to interest physicians and
patients alike. Among the most important and complex of these are the associations of
alcohol use with cardiovascular and neurovascular diseases, such as coronary heart disease
(CHD) and stroke.
Two large prospective cohort studies have recently examined alcohol intake and these
diseases: the Health Professionals Follow-up Study (HPFS) (Mukamal et al., 2003a) and the
Cardiovascular Health Study (CHS) (Mukamal et al., 2006). Both are carefully-administered
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longitudinal studies with repeated measures of alcohol intake and validated assessment of
cardiovascular disease incidence over 10–20 years. The populations differ to a substantial
degree—HPFS enrolled over 50,000 middle-aged male health professionals from around the
U.S., while CHS is a population-based study of almost 6,000 older adults from four U.S.
communities—but they have produced remarkably similar findings on the relation of alcohol
intake with cardiovascular disease.
The association of alcohol use with CHD has undoubtedly been the focus of the most
observational studies. Several meta-analyses have come to generally similar conclusions
about the relationship of average alcohol consumption with risk, suggesting ~25% lower risk
throughout a range of intake from about ½ drink per day through two drinks per day, but
potentially higher risk at or above six drinks per day (Cleophas, 1999; Corrao et al., 2000;
Maclure, 1993). This association has been observed for over three decades (Klatsky et al.,
1974) and in populations worldwide consuming a variety of alcoholic beverages (Brenner et
al., 2001; Yuan et al., 1997). At the same time, concern continues to be raised about whether
the lower risk associated with alcohol intake is related to bias by inclusion of former
drinkers with pre-existing illness or confounding by lifestyle factors associated with
moderate drinking (Freiberg and Samet, 2005).
In both HPFS and CHS (Figure 1), strong, graded, inverse associations of alcohol intake
with risk of CHD were found (Mukamal et al., 2006;Mukamal et al., 2003a). Former
drinkers were separated from longer-term abstainers in both cases, and the results
demonstrated little difference in risk between abstainers and very light drinkers, suggesting
that the choice of reference group did not bias the findings. It was possible to account for a
large number of sociodemographic and clinical characteristics, and findings were similar for
a variety of CHD-related outcomes. In both studies, risk was approximately 25–30% lower
among consumers of 1 drink per day than among abstainers. No clear advantage was
observed for any one beverage type in either study, suggesting that alcohol per se is most
likely to be the active constituent, at least at the doses of alcoholic beverages normally
consumed.
Several plausible mechanisms for the association of alcohol intake with lower risk of CHD
exist. Randomized crossover feeding studies clearly show that alcohol intake raises high-
density lipoprotein cholesterol (HDL-C) in an approximately dose-dependent manner and to
a greater degree than currently available pharmacological options (Rimm et al., 1999). In the
CHS and HPFS, alcohol intake correlates well with HDL-C levels, with coefficients of
~0.25–0.35. The effect of alcohol on HDL-C alone appears to explain 50–70% of the
observed inverse association of alcohol with risk of CHD (Mukamal et al., 2005c; Rimm et
al., 1999). Other feeding studies, including the longest randomized trial conducted to date
(Marfella et al., 2006), also support a benefit of alcohol intake on insulin sensitivity (Davies
et al., 2002) and on inflammatory markers (Sierksma et al., 2002b). Whether alcohol also
provides direct cardioprotection from myocardial ischemia has not been determined in
humans, but analyses of the Determinants of Myocardial Infarction Onset Study (which
included nearly 4,000 patients with acute myocardial infarction) raise the possibility that
alcohol consumed 6–12 hours prior to onset of ischemia could attenuate infarct size
(Mukamal et al., 1999).
Despite similarities between CHD and stroke, their associations with alcohol intake appear
quite different. In both HPFS (Mukamal et al., 2005a) and CHS (Figure 1) (Mukamal et al.,
2005b), lower risk of ischemic stroke was limited to alcohol consumption weekly but less
than daily and with a substantially weaker magnitude than was seen for CHD. In HPFS,
alcohol intake above two drinks per day was clearly associated with higher ischemic stroke
risk. Meta-analyses of alcohol and stroke support this fully (Reynolds et al., 2003),
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suggesting ~20% lower risk of ischemic stroke among less-than-daily drinkers in cohort
studies, but increased risk with heavier drinking, and a dose-dependent increase in risk for
hemorrhagic stroke. Consumption of three or more drinks in one day also appears to acutely
trigger ischemic stroke (Hillbom et al., 1995).
Interest in the association of alcohol intake with dementia has been fueled by the recognition
that dementia shares several risk factors with cardiovascular disease. In the CHS, a U-
shaped relationship of alcohol intake with risk of dementia (see Figure 1) was observed,
with similar findings for vascular dementia and Alzheimer disease. This U-shape exactly
parallels findings on alcohol intake and MRI-identified cerebral white matter lesions
(Mukamal et al., 2001), which are strong predictors of dementia in CHS (Kuller et al.,
2003). Although dementia was not assessed in HPFS, findings from the Nurses’ Health
Study, a parallel cohort of women, also support better cognitive function among women who
consume alcohol within recommended ranges (Stampfer et al., 2005). However, data from
other studies appear somewhat mixed (Dufouil et al., 2000;Larrieu et al., 2004;Luchsinger et
al., 2004;Ruitenberg et al., 2002;Truelsen et al., 2002), and this remains an important area
for future investigation.
Thus alcohol intake has a complex associations with cardiovascular and neurovascular
diseases. These include dose-dependent associations of alcohol with lower risk of CHD but
higher risk of hemorrhagic stroke throughout a recommended range of drinking, an
increased risk of ischemic stroke with heavier drinking, and an emerging but somewhat
variable association with lower risk of dementia.
MODERATE ALCOHOL AND PROTECTION AGAINST CARDIAC ISCHEMIA-
REPERFUSION (I/R) INJURY: INVOLVEMENT OF PKCepsilon
Moderate alcohol consumption, one drink or less per day for women and two drinks or less
per day for men, has been found to reduce the incidence and adverse consequences of heart
disease in a series of epidemiological studies. For example, Mukamal and coworkers
(Mukamal et al., 2005d) showed that alcohol consumption at least three to four days per
week was associated with a lower risk of myocardial infarction among men and women.
Importantly, this association was attributed to physiologically relevant trends in HDL
cholesterol, fibrinogen, and hemoglobin A1C. Clinical trials of short-term alcohol intake are
scarce but suggest that moderate drinking enhances insulin sensitivity (Davies et al., 2002)
and decreases plasma levels of C-reactive protein and fibrinogen (Sierksma et al., 2002a).
Long-term clinical trials to examine effects of moderate drinking on coronary artery disease
outcomes are highly controversial and not likely to be conducted within the United States.
With a focus on the identification of intracellular signaling pathways activated by moderate
alcohol consumption that preserve viability and contractile function of cardiac tissue during
stress, adult rodent protocols have been carried out that simulate human drinking patterns to
test the hypothesis that moderate alcohol concentrations trigger protective signaling in
ventricular heart cells, thereby increasing resistance to acute ischemia-reperfusion injury. In
such studies, moderate concentrations in rats produced sustained cardioprotection requiring
activation of mitochondrial KATP channels (Zhu et al., 2000), consistent with experiments
published by other laboratories using canine models (Pagel et al., 2002). Also, acute (Chen
et al., 1999) and chronic (Zhou et al., 2002) cardioprotection stimulated by physiological
concentrations of alcohol were associated with the selective activation of protein kinase
Cepsilon (PKCε). This isoenzyme is recognized as a powerful cytoprotectant in myocytes,
through interactions with substrates and anchoring molecules in numerous compartments
(Ping et al., 2001).
Collins et al. Page 4
Alcohol Clin Exp Res. Author manuscript; available in PMC 2010 July 22.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
In a typical experiment, adult male C57BL/6 mice ingest 10% ethanol (vol/vol) as the sole
source of drinking water for 12 weeks (Zhou et al., 2004). The protocol produces blood
alcohol concentrations of approximately 10 mg/dL or 4 mM at the time of sacrifice (and
maximal night-time concentrations in comparable alcohol consumption studies of
approximately 13 mM or 67 mg/dL remain in a moderate range) (Chen et al., 2003).
Alcohol-fed animals appear normal in the cage environment and maintain predicted body
weights. However, the hearts of alcohol-fed mice are much more resistant to stress than
control hearts, with decreased infarction size and improved contractile recovery after
simulated ischemia-reperfusion. Importantly, cardiac myocytes isolated from alcohol-fed
mice are resistant to in vitro stress. As shown in Figure 2, control cells rapidly lose their
capacity to exclude trypan blue dye during incubation with H2O2-supplemented culture
medium. In contrast, cell survival under the same oxidative conditions is significantly
greater in myocyte cultures prepared from the ventricles of alcohol-fed animals. These
results confirm that moderate alcohol concentrations are cardioprotective, at least in part,
through direct and sustained effects on cellular mechanisms intrinsic to ventricular
myocytes.
Mitochondria produce most of the ATP required for cardiac contractile activity. In addition,
these organelles generate reactive oxygen species that contribute to both physiological heart
function and pathological tissue damage. Previous experience with the effects of alcohol on
mitochondrial KATP channel activity and PKCε expression prompted investigations of PKCε
localization in heart mitochondrial fractions before and after chronic alcohol feeding and
acute ischemia-reperfusion. As indicated in Figure 3A, chronic moderate alcohol
consumption does not produce significant differences in mitochondrial PKCε expression
under baseline conditions. However, localization of PKCε to mitochondrial fractions is 3-
fold greater after ischemia-reperfusion in the hearts of alcohol-fed mice compared to
controls. These data suggest that alcohol pretreatment promotes rapid recruitment of PKCε
during stress to heart mitochondria, where PKCε has been shown by other groups to
preserve organelle integrity (Baines et al., 2003).
Accordingly, microassays to measure the activity of NADH-ubiquinone (Q1) reductase, or
Complex I, in submitochondrial particles prepared from individual mouse hearts have been
developed (Zhou et al., 2004). As shown in Figure 3B, moderate alcohol concentrations did
not produce significant differences in mitochondrial Complex I activity under baseline
conditions. However, alcohol ingestion doubled Complex I activity after ischemia-
reperfusion compared to controls. Pretreatment of isolated hearts with a specific PKCε
antagonist peptide (Gray et al., 2004) prior to ischemia-reperfusion blocked alcohol-induced
cardioprotection. In the above report, hearts from PKCε null mice fed 10% alcohol for 12
weeks did not exhibit protection against Complex I injury compared to controls. These
results signify that moderate alcohol concentrations decrease damage to the mitochondrial
respiratory chain complex most sensitive to the stress of ischemia-reperfusion and support
the key role of PKCε activation in sustained alcohol-mediated cardioprotection.
Overall, a mouse model of consumption that realizes moderate but not high alcohol
concentrations points to sustained PKCε activation in ventricular myocytes as mediator of
resistance to ischemia-reperfusion injury. The experimental system is highly stable and may
be more relevant to human cardiac physiology than genetically engineered mice that express
a constitutively active form of PKCε (Ping et al., 2001). Hearts from alcohol-treated animals
are being used to explore downstream mechanisms of chronic cardioprotection through
conventional protein methods and unbiased approaches such as microarray analysis, with
one principal objective of this research to better understand the relationship between alcohol
consumption and heart disease, particularly for individuals who drink in moderation.
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Alternatively, this line of investigation may reveal cardioprotective targets that do not
require alcohol ingestion, thus circumventing toxic effects on other organ systems.
ALCOHOL AND CARDIOVASCULAR PROTECTION via NITRIC OXIDE
PATHWAYS
Coronary heart disease (CHD) remains the leading cause of death in both men and women in
the United States (Klatsky, 1996). In patients with cardiovascular risk factors such as
hypercholesterolemia, hypertension or aging (Zeiher et al., 1993) endothelial dysfunction
predisposes to the development of structural vascular changes (Ross, 1993) and may play a
critical role in acute myocardial infarction and sudden death. Heavy alcohol consumption
has long been associated with vascular as well as myocardial complications (Klatsky, 1996),
whereas, as discussed earlier in this summary, several epidemiological studies suggest an
inverse association between long-term moderate alcohol consumption and the risk of CHD
and myocardial infarction (Thun et al., 1997) as well as a reduction in mortality (Doll,
1997).
This cardioprotection has been attributed to the direct effects of moderate alcohol and/or
polyphenols in increasing high-density lipoproteins (Gaziano et al., 1999; McConnell et al.,
1997), decreasing platelet aggregation (Renaud and Ruf, 1996), enhancing fibrinolytic
activity, decreasing fibrinogen (Aikens et al., 1998; Ridker et al., 1994) and decreasing
ischemia-reperfusion injury (Miyamae et al., 1997). There is accumulating evidence that
cardioprotection associated with moderate alcohol consumption involve cellular and
molecular mechanisms related to nitric oxide (NO). Nitric oxide is generated by three
isoforms of nitric oxide synthase (NOS). Endothelial NOS (eNOS) is a key regulator of
vascular homeostasis, including basal vascular tone (blood flow) and blood pressure (Patel
et al., 1999; Radomski and Moncada, 1993). Cardiac myocytes also constitutively express
eNOS, which contributes to the regulation of myocardial contractility, heart rate (Kojda and
Kottenberg, 1999) and cardiac oxygen consumption (Loke et al., 1999). Upregulation of
eNOS has been postulated to play a protective role in both congestive heart failure (Khadour
et al., 1998) and myocardial ischemia-reperfusion (Kanno et al., 2000; Sumeray et al.,
2000). NO also inhibits smooth muscle proliferation, platelet aggregation and monocyte
adhesion making it an anti-thrombogenic agent (Lamas et al., 1998).
In a paired feeding paradigm, male Sprague-Dawley rats consumed an alcohol (ethanol)-
containing or equicaloric liquid diet in which alcohol comprised 0, 9 or 18% of the total
calories for 8 weeks. At 8 weeks, animals were anesthetized and myocardial function
accessed after 20 min ischemia and 30 min reperfusion using a modified Langerdorf
preparation. Moderate alcohol consumption enhanced post-ischemic myocardial systolic and
diastolic function as well as attenuated the ischemia-induced increase in coronary vascular
resistance. In a separate series of experiments, vascular function was assessed in isolated
thoracic aorta ring segments. Acetylcholine was added to stimulate endothelial cell NO
formation via the mobilization of intracellular Ca++, which activates eNOS and invokes
endothelium-dependent relaxation. Moderate alcohol consumption for 8 weeks significantly
increased maximal amplitude for vascular relaxation, consistent with upregulation of eNOS.
There was a paradoxical impairment in vessel relaxation with higher doses of alcohol
consumption. Immunolocalization of eNOS protein confirmed moderate alcohol
consumption increased eNOS protein expression in the vascular endothelium of the vascular
endothelium. Finally, total nitrates and nitrites were increased in the blood of rats after 8
weeks consumption of moderate alcohol, suggesting a functional eNOS protein increase
(Abou-Agag et al., 2005).
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The characteristics of the cardioprotection associated with consumption of alcoholic
beverages are indicative of mechanisms resulting in improved functional and metabolic
performance in both the myocardium and vasculature. There are a number of actions of NO
that would be predicted to be cardioprotective, including decreased cardiac contractility
(Kitakaze et al., 1996; Lamas et al., 1998), decreased coronary resistance (Kitakaze et al.,
1996), diminished myocardial oxygen consumption (Okubo et al., 1999), and improved
metabolic function (Kanai et al., 1997). Increased NO bioavailability may play an important
role in alcohol-dependent cardioprotective mechanisms through the regulation of antioxidant
and NO producing enzymes.
ALCOHOL CARDIOPROTECTION MECHANISMS WITH ADDITIONAL
CONSIDERATION OF THE CONTRIBUTION OF RESVERATROL
Epidemiological evidence strongly suggests that light-to-moderate alcohol drinking, usually
defined as consumption of 1 to 2 drinks per day [less than 30 gm/day], is associated with a
reduced risk of CHD including ischemic heart disease, cardiomyopathy, diabetes, and stroke
(Zakhari, 1999). Heavy drinking (more than 3 drinks per day), on the other hand, adds
further to the complications in CHD. A J- or U-shaped relationship exists between the
amount of alcohol drinking and CHD (Djousse et al., 2002), indicating that risk of death due
to CHD is the lowest among the moderate drinkers as compared to abstainers or heavy
drinkers. Cardioprotective effects of moderate alcohol drinking include reduction of platelet
aggregation and fibrinogen levels leading to increased fibrinolysis, coronary blood flow and
reduced blood pressure; increased HDL and reduced LDL resulting in lowering of risk due
to cholesterol; reduction of insulin resistance and increase in insulin sensitivity; and
reduction of blood homocysteine levels (Figure 4A).
Precise mechanisms for the cardioprotective effects are not known; however, several
experimental studies have shed some light on the mechanisms of action of light to moderate
drinking. In one of such studies, guinea pigs were given alcohol in their drinking water for
3–12 weeks and at the end, the hearts were isolated and subjected to ischemia reperfusion
injury (Miyamae et al., 1997). Hearts from animals drinking alcohol showed improved
functional recovery and decreased myocyte damage when compared with controls.
Adenosine A1 receptor blockade abolished the protection, suggesting a role of adenosine A1
receptor in cardioprotection. In another study, the rats were made diabetic with
streptozotocin, and then given alcohol for a month. The diabetic rats fed an alcohol diet
showed a 52% reduction in advanced glycation end product when compared with diabetic
controls (Al-Abed et al., 1999). In rabbit heart alcohol was found to exert a preconditioning-
like effect mediated through adenosine receptors, PKC, and mitochondrial KATP channels
(Krenz et al., 2004). In in vitro studies mentioned earlier, rat heart cardiomyocytes were
protected from ischemic injury by alcohol through the upregulation of PKCε (Chen et al.,
1999), and also, alcohol-mediated cardioprotection was achieved through the upregulation
of eNOS expression (Abou-Agag et al., 2005). In rat heart, direct alcohol feeding led to a
reduction of apoptotic cardiomyocyte death by reducing apoptotic signaling cascades,
JNK-1 and c-Jun, and activating heat shock protein (HSP) 70, heme oxygenase and
superoxide dismutase (Sato et al., 2004). Another study, also cited earlier in this summary,
demonstrated that alcohol triggered anti-death signals by activating Akt (Zhou et al., 2002).
The mechanisms of action of alcohol-mediated cardioprotection known to date are
summarized in Figure 4A.
There is no direct clinical study demonstrating the mechanisms of cardioprotection afforded
by light-to-moderate alcohol consumption. Nevertheless, clinical studies exist showing that
moderate alcohol consumption leads to a reduction of serum lipids, lipoproteins, platelets,
LDL and inflammatory cytokines, and increased HDL (Lucas et al., 2005). Overwhelming
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epidemiological evidence, however, exists in support of alcohol-mediated cardioprotection.
All the risk factors of CHD including diabetes, hypercholesterolemia, smoking and stroke
are modulated by low-to-moderate alcohol consumption (Djousse et al., 2002).
A last point is that most of the experimental studies related to alcohol-mediated
cardioprotection that originate in Europe use wine, especially red wine, while American
studies typically use alcohol itself. Although part of the wine-mediated cardioprotection may
be attributed to the alcohol (wines typically contain 10–12% alcohol), cardioprotective
properties of red wine can be correlated with the presence of polyphenolic antioxidants,
especially resveratrol, which is concentrated in red wine (Das and Maulik, 2006), but also in
other alcoholic beverages (albeit in lower amounts) such as beers (Callemien et al., 2005).
Whether resveratrol is the essential component that is responsible for much of the
cardioprotective effects of wine or the alcohol that is present in wines and is responsible for
cardioprotection remains under considerable debate, but there is no doubt that resveratrol
may protect the heart in many ways (Das et al., 2008; Juric et al., 2007; Lekli et al., 2008;
Mokni et al., 2007), not to mention the brain with regard to stroke (Tsai et al., 2007). At any
rate, it is interesting to note that there are many similarities in the cardioprotective
mechanisms of action and molecular targets between resveratrol and alcohol (Figure 4A and
Figure 4B) that may force the rethinking of the relative significance of alcohol vs.
resveratrol in health and disease.
ANTECEDENT ALCOHOL PREVENTS MICROVASCULAR DYSFUNCTION IN
I/R THROUGH ANTI-INFLAMMATORY AND ANTI-ADHESIVE MECHANISMS
The possibility that ingestion of alcoholic beverages might be associated with
cardioprotective effects was first appreciated by consideration of epidemiologic data
indicating that long-term, regular consumption of red wine at low to moderate levels (1 to 3
drinks per day for months to years) correlated with decreases in the incidence of coronary
artery disease as well as improved survival in patients suffering myocardial infarctions (Das
and Ursini, 2002; Korthuis, 2004). Although the antioxidant properties of red wine
constituents were originally thought to largely explain its cardioprotective effects,
subsequent epidemiologic evidence has indicated that consumption of white wine, beer, or
spirits is also beneficial (Das and Ursini, 2002; Korthuis, 2004; Shigematsu et al., 2003).
The latter observations pointed to the importance of alcohol per se in the beneficial actions
of alcohol intake on cardiovascular mortality. While subsequent studies established that the
cardioprotective effects of moderate alcohol consumption could be partially explained by
effects on plasma lipids, platelet function, and fibrinolytic activity, alcohol intake maintains
a significant association with reduced cardiovascular mortality even after controlling for
lipoprotein and hemostatic factors. More recent work indicates that alcohol administration
24 hrs prior to I/R (referred to as antecedent alcohol, equivalent to alcohol preconditioning,
but with trace residual alcohol levels during I/R) induces the development of an anti-
inflammatory phenotype in postcapillary venules such that these vessels fail to express P-
selectin or support leukocyte adhesion and emigration in postischemic tissues (Dayton et al.,
2005; Gaskin et al., 2007; Kamada et al., 2004; Wang et al., 2007; Yamaguchi et al., 2007).
In addition, alcohol consumption at low to moderate levels is associated with reduced C-
reactive protein levels, a plasma marker of inflammation, and decreased production of
inflammatory cytokines such as interleukin-6 (Albert et al., 2003; Das and Ursini, 2002;
Korthuis, 2004; Korthuis, 2006). Given the critical importance of infiltrating leukocytes in
the pathogenesis of atherosclerosis and I/R injury, these new observations provide novel
insight regarding the mechanisms whereby alcohol ingestion reduces the likelihood and
extent of I/R injury in individuals at risk for cardiovascular disease.
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The anti-adhesive effects of antecedent alcohol intake on postischemic leukosequestration
has been extensively studied using intravital microscopic approaches, which allow direct
quantification of leukocyte rolling, stationary adhesion, and emigration in single
postcapillary venules in real time. Yamaguchi and coworkers (Yamaguchi et al., 2007) were
the first to demonstrate that acute intubation of a low-moderate dose of alcohol in mice
(>0.5 g/kg; ~300 μl vol.) completely prevents adhesive interactions between circulating
leukocytes and the endothelium from developing in tissues exposed to subsequent I/R. The
temporal expression of this protected or preconditioned state induced by alcohol ingestion
was biphasic. The initial phase (acute alcohol preconditioning) develops rapidly, involves
activation of pre-existing effector molecules, and is short-lived, with peak anti-inflammatory
effects (50% reduction in leukocyte adhesion) occurring 2 to 3 hours after intake, and then
disappearing by 4 hours after administration. The second or delayed phase of ischemic
tolerance induced by alcohol emerges 12 to 24 hours after alcohol intake, is longer-lived (24
hrs or more), requires the expression of new gene products, and is notable for its magnitude
of protection, completely preventing postischemic leukocyte rolling and adhesion (Kamada
et al., 2004; Korthuis, 2006; Yamaguchi et al., 2007). In these studies, plasma alcohol levels
peaked at 45mg/dL within 30 minutes of gastric instillation by gavage and returned to
control levels within 60 minutes of ingestion. This observation indicates that neither the
acute phase of protection that arises within 1 to 3 hours of alcohol ingestion nor the late
phase that reemerges 12 to 24 hours later are due to direct effects of alcohol. Indeed, alcohol
must be largely absent before the cardioprotective effects of the alcohol become apparent.
Because late phase alcohol preconditioning exerted much more powerful and long-lived
effects, most subsequent studies have focused on elucidation of the mechanistic
underpinnings for this latter phase. As a result of this work, it has become apparent that the
factors that contribute to the development of tolerance to ischemia can be conceptually
compartmentalized into: 1) triggers that inaugurate entrance into the anti-inflammatory
phenotype, 2) downstream signal transducers that are activated by the initiating factors and
induce an increase in activity or expression of 3) end-effectors that mediate the anti-adhesive
effects noted during I/R 24 hrs after ingestion (Kamada et al., 2004; Korthuis, 2006).
Early work in this area focused primarily on uncovering the initiators of alcohol
preconditioning, as this may provide important clues towards the development of rational
therapeutic interventions that could be used in lieu of alcohol to induce similar
cardioprotective effects, but avoid potential untoward physiologic and social effects
associated with alcohol consumption. The well-known effect of alcohol to inhibit nucleoside
transporters in cell membranes (thereby limiting adenosine reuptake into cells) led to the
postulate that adenosine might serve as a trigger for entrance into the anti-inflammatory state
induced by adenosine. Pharmacologic inhibitor studies support this concept and indicated
that adenosine A2 receptor occupancy is required for this process (Yamaguchi et al., 2007).
Uncovering the role of adenosine A2 receptors was an important mechanistic distinction as
the downstream signaling elements activated by adenosine A1/A3 versus A2 receptors are
very different. Indeed, adenylyl cyclase or protein protein kinase A blockade, but not PI3
kinase inhibitors, prevents the late phase of alcohol preconditioning (Kamada et al., 2004;
Korthuis, 2006). On the other hand, administration of adenosine A2 receptor agonists, cell-
permeant cyclic AMP analogs, or adenylyl cyclase activators (e.g., isoproterenol, forskolin)
mimics the postischemic anti-inflammatory effects of late-phase alcohol preconditioning.
Because alcohol enhances both basal and flow-stimulated NOS activity and NO production
in vivo and in cultured endothelial cells, it has been suggested that production of this
gaseous monoxide during the period of alcohol exposure may also serve as an important
triggering element for the late phase of alcohol preconditioning (Wallerath et al., 2003;
Yamaguchi et al., 2002; Yamaguchi et al., 2007). Support for this concept is derived from
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four lines of evidence. First, administration of NOS antagonists just prior to, but not 1 hour
after, alcohol administration on day 1 abolishes the anti-adhesive effects of late alcohol
preconditioning on day 2 (Yamaguchi et al., 2002; Yamaguchi et al., 2003; Yamaguchi et
al., 2007). The latter observation supports the concept that NO plays an important role in
promoting the development of the anti-inflammatory phenotype that becomes apparent 18 to
24 hours later. Second, plasma levels of nitrite/nitrate, a marker for NO production, are
increased during the period of alcohol exposure (Yamaguchi et al., 2007). Third, tissues
pretreated with NO donors in lieu of alcohol develop an antiinflammatory phenotype 24
hours after administration (Yamaguchi et al., 2002; Yamaguchi et al., 2007). Finally, the
anti-inflammatory phenotype induced by alcohol does not appear in mice that are genetically
deficient in eNOS (Yamaguchi et al., 2007). This last finding not only provides the fourth
line of evidence supporting a role for NO as a triggering element in alcohol preconditioning,
but also indicates that the eNOS isoform is essential for the development of the anti-
inflammatory phenotype in response to alcohol. Interestingly, NO donors remain effective as
preconditioning stimuli in eNOS-deficient mice, indicating that downstream mediators of
preconditioning remain effective in these mice.
As mentioned in an earlier section of this workshop summary, the factors responsible for
increasing eNOS activity in late alcohol preconditioning (or any form of preconditioning for
that matter) are largely unknown; however, it now appears that this effect is triggered by an
adenosine A2 receptor dependent mechanism (Yamaguchi et al., 2002; Yamaguchi et al.,
2007). This notion is supported by the observations that ligation of adenosine A2 receptors
increases the activity of cAMP-dependent kinase (PKA), which in turn activates eNOS by
phosphorylating Ser-1177. Moreover, adenosine stimulates l-arginine transport and NO
biosynthesis by activation of A2 receptors on human umbilical vein endothelial cells. More
recent work has established that AMP kinase activation may also play a critical role as an
upstream signaling step in eNOS-dependent preconditioning by alcohol (Gaskin et al.,
2007).
Another well-known effect of alcohol is to increase the generation of reactive oxygen
species, including superoxide and the hydroxyethyl radical (Das and Vasudevan, 2007).
Although they are generally considered to exert deleterious effects in biologic systems, it is
becoming increasingly apparent that reactive oxygen species may participate in a number of
normal physiologic phenomena by serving as second messengers in transmembrane
signaling processes. Indeed, administration of a cell-permeant superoxide dismutase (SOD)
mimetic, the porphyrin MnTBAP, coincident with alcohol prevents the postischemic
antiadhesive effects that become apparent 24 hours after ingestion of the alcohol
(Yamaguchi et al., 2003). Moreover, exposing postcapillary venules to a superoxide
generating system (hypoxanthine/xanthine oxidase) 24 hours prior to I/R mimicked the
antiadhesive effects produced by antecedent alcohol exposure. Additional support for the
concept that oxidants may participate in triggering the development of the anti-inflammatory
phenotype in response to antecedent alcohol ingestion is derived from studies directed at
elucidating their source of production. Inhibition of either xanthine oxidase or NADPH
oxidase alone attenuated the anti-adhesive effects of alcohol preconditioning by 50 percent,
whereas concomitant inhibition of both oxidant-producing enzymes effectively prevented
the development of the protected phenotype (Yamaguchi et al., 2003). The latter studies
indicate that xanthine oxidase and NADPH oxidase are important enzymatic sources of the
reactive oxygen species that trigger entrance into the anti-inflammatory phenotype displayed
by postcapillary venules exposed to alcohol 24 hours prior to I/R. These observations have
been extended to stroke models where antecedent alcohol has been shown to reduce I/R-
induced delayed neuronal death, neuronal and dendritic degeneration, oxidative DNA
damage, glial cell activation and neutrophil infiltration. These beneficial actions of alcohol
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preconditioning were prevented by treatment with a SOD mimetic or an NADPH oxidase
inhibitor (Wallerath et al., 2003).
As noted earlier, there is evidence implicating NO, formed secondary to adenosine A2-
receptor-dependent activation of endothelial NOS, in the beneficial actions of antecedent
alcohol ingestion. This raises the possibility that NO produced during the period of alcohol
preconditioning initiates the protective effects of late alcohol-PC by a mechanism that
involves its interaction with xanthine oxidase- and/or NAD(P)H oxidase-derived oxidants.
This is an important issue because isoform-selective PKC translocation and activation
appears to play a critical role as an obligatory downstream signaling element in late alcohol
preconditioning (Dayton et al., 2005). However, NO and NO-releasing agents reversibly
inactivate PKC. On the other hand, peroxynitrite, which is formed by the interaction of NO
with superoxide, not only induces PKC activation, but has been implicated as a trigger for
the beneficial actions of other forms of preconditioning including that induced by antecedent
exposure to brief ischemia. Taken together, these observations suggest that reactive NO
species formed secondary NO/superoxide interactions may be required to induce the
development of alcohol preconditioning (Dayton et al., 2005; Yamaguchi et al., 2003).
Although the mediators of late phase alcohol preconditioning are unclear, the time course
required for its development suggests that the appearance of the protected phenotype 18 to
24 hours after alcohol ingestion requires the formation of new gene products capable of
producing anti-inflammatory agents. In this regard, it is tempting to speculate that alcohol
might enhance the expression of cyclooxygenase-2, inducible NOS (iNOS), or heme
oxygenase-1 (HO-1), which in turn generate prostacyclin and other eicosanoids, NO, and
carbon monoxide, respectively, all of which produce robust antiadhesive effects in
postcapillary venules. In addition to carbon monoxide, HO-1 also generates the powerful
antioxidants bilirubin and biliverdin, which may act to prevent the formation of oxidant-
dependent chemoattractants during I/R. It is also possible that alcohol may exploit the anti-
adhesive properties of adenosine as a mediator of the preconditioned state secondary to
enhanced production or decreased salvaging (via activation of 5′-nucleotidase or inhibition
of adenosine kinase, respectively) of the nucleoside in postischemic tissues. The fact that an
anti-inflammatory phenotype does not become apparent in mice treated with a
pharmacologic HO inhibitor during reperfusion and fails to develop in HO-1 knockout mice
suggests that this protective protein may serve as a major effector.
NEUROPROTECTIVE MECHANISMS EVOKED IN BRAIN BY
PRECONDITIONING WITH MODERATE ALCOHOL CONCENTRATIONS
As indicated in Figure 1, moderate alcohol consumption has sometimes been associated in
case-control studies with a lower risk of dementia (Mukamal et al., 2003b). Additionally, the
epidemiological literature contains about 19 longitudinal cohort studies between 1997 and
2008 (Mehlig et al., 2008;Orgogozo et al., 1997) that compare relative risk factors for either
cognitive decline or dementia—both Alzheimer’s and cerebrovascular—in older moderate
alcohol consumers versus abstainers/never-drinkers. In these studies, over half (~54%) of
the risk factors were significantly lower in moderate consumers. The remaining studies’ risk
factors did not differ between the two groups, with the exception of 2 studies with risk
factors (~5% of the total) that were increased by moderate drinking. Also, in 25 other cross-
sectional or case-control reports of cognitive decline or dementia, a similar majority of the
risk factors were significantly decreased in association with moderate consumption. The
authors of the studies finding lower cognitive risk factors viewed the apparent age-
dependent neuroprotection as the outcome of alcohol’s beneficial hematologic,
cardiovascular and possibly cerebrovascular effects (see Figure 4A), as well as perhaps
related to beverage anti-oxidant polyphenols (e.g., resveratrol—Figure 4B) (Pinder and
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Sandler, 2004) that can act within the nervous system. However, alcohol in moderate levels
conceivably exerts its own “direct” neuroprotective effects that are under current study with
antecedent exposure, co-exposure, and preconditioning models.
The phenomenon of preconditioning tissues or cells to generate a cytoprotective state or
“phenotype” has been appreciated for some time (Gidday, 2006). Brief ischemia that can
generate ischemic tolerance has been studied extensively in the heart and, more recently, the
brain. Ischemic or hyperthermic preconditioning and brain neuroprotection, first described
only about two decades ago (Chopp et al., 1989; Kitagawa et al., 1990), has spawned studies
with traditionally toxic agents at exposures that mildly stress and thus precondition the
system under study (Best et al., 1996; Leak et al., 2006; Nvue et al., 2004). Moreover,
preconditioning-dependent protection by alcohol against ischemic insult of the heart is
attested to in many studies, as related earlier in this review (Agarwal, 2002; Sato et al.,
2004), and the process is considered a likely component of cardioprotection in moderate
alcohol drinkers (Miyamae et al., 1997).
With the exceptions of several in vivo reports and a series of in vitro studies, neuroprotection
due to either antecedent alcohol or alcohol preconditioning has been relatively overlooked.
In an in vivo report mainly concerned with alcohol and the blood/brain barrier, neurons in
brain cortices of adult male “alcohol-preferring” rats chronically consuming 15% alcohol/
water were found to be protected from apoptosis due to peripherally injected pro-
inflammatory lipopolysaccharide (Singh et al., 2007); however, a mechanistic interpretation
was not provided. In ischemia studies mentioned above, antecedent moderate alcohol
triggered significant neuroprotection against I/R hippocampal neuronal injury in an adult
gerbil model (Wang et al., 2007), and reactive oxygen species (ROS) induction secondary to
increased NADPH oxidase activity was implicated in alcohol’s protective effect. In adult
rats, icv alcohol (~0.7 umoles over 4 hr) pre- (or post-) I/R was neuroprotective (Liao et al.,
2003), and the mechanism was ascribed to ROS trapping by alcohol (Cohen et al., 1976).
In brain cultures, non-neurotoxic alcohol co-exposure can block excitotoxic (N-methyl-D-
aspartate [NMDA] receptor-mediated) neurodegeneration (Belmadani et al., 2003; Cebere
and Liljequist, 2003; Chandler et al., 1993; Wegelius and Korpi, 1995), consistent with
NMDA receptor antagonism by alcohol. However, alcohol preconditioning (at least in vitro)
circumvents the issue of direct blockade of NMDA receptor activity by alcohol during the
neurotoxic insult in question. Alcohol preconditioning effects on inflammatory protein
neurotoxicity were explored with organotypic slices of the maturing rat hippocampus-
entorhinal cortex (HEC) complex—which incorporates two brain regions significantly
impacted in Alzheimer’s dementia and other dementias—as well as with mixed cerebellar
cultures (Collins et al., 2000). Several neurotoxic HIV-1 proteins have been studied, and
notably, glycoprotein 120 (gp120), the most potent in the laboratory, which can cause
neuronal degeneration and apoptosis at low picomolar (10−12 molar) concentrations in
hippocampal slice cultures (Aggoun-Zouaoui et al., 1996) and other brain cultures
(Brenneman et al., 1988). Of importance, moderate (15–30 mM) subchronic alcohol
preconditioning of HEC slice and cerebellar cultures prevented gp120IIIB-induced
neurodegeneration (Belmadani et al., 2001; Collins et al., 2000).
Neuroinflammatory processes originating from gp120IIIB interactions with glial chemokine
receptors generate neurodegenerative cascades (Kaul and Lipton, 2006). The alcohol
preconditioning, which was delayed in that it required >4d of alcohol exposure for
neuroprotection, effectively blunted or suppressed several neuroinflammatory processes or
events soon after gp120 addition—e.g., increases in [Ca+2]i, arachidonic acid release, tissue
superoxide, and extracellular glutamate (Belmadani et al., 2001). Considerable research
indicates that heat shock proteins (hsp) can be putative neuroprotective “effectors” induced
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by ischemic and other delayed preconditioning approaches (Carmel et al., 2004; Gidday,
2006). In that regard, significant induction of hsp70 (Belmadani et al., 2004) and hsp27
occurred in HEC slices after ~6 d of moderate alcohol exposure—but not at 4 d—which
correlates with the onset of significant neuroprotection. Furthermore, phosphorylated hsp27
(p-hsp27), known to colocalize with cytoskeletal elements and particularly actin, was
increased at 6 d of alcohol preconditioning both in HEC slices and cerebellar cultures
(Sivaswamy et al., 2008). The results from co-treatment with the pharmacologic heat shock
inhibitor, quercetin (5 uM, a nontoxic dose that blocks ~80% of hsp induction), indicated
that induced hsps are critical components of neuroprotection against gp120, since quercetin
abolished the preconditioning neuroprotection while concomitantly restoring the superoxide
potentiation.
Studies with more common preconditioning modalities—in particular, ischemic tolerance—
have elucidated the involvement of early cellular “sensors” that trigger subsequent
“transducer” mechanisms such as kinases, cytokines and transcription factors upstream of
hsp effectors (Dirnagl et al., 2003). Sensors include glutamate receptors (notably the NMDA
receptor channel), adenosine receptors, and perhaps others coupled to Gi proteins;
transducers include PKC isoforms and possibly other kinases. Alcohol preconditioning
experiments with mixed cerebellar cultures using receptor antagonists for NMDA receptors,
memantine or AP-5, indicated that neuroprotective activation of this “sensor” receptor is
important during the first day or so of alcohol exposure (Mitchell et al., 2007). Consistent
with these findings is that NMDA receptor stimulation directly with (sub-neurotoxic)
NMDA preconditions the cultures, neuroprotecting against β-amyloid. In the case of
alcohol, western blotting data indicate significant changes in NMDAR subunit (NR1,
NR2A, NR2C) ratios during the early part of preconditioning that could be important in this
receptor’s involvement. Parenthetically, there is evidence that subchronic alcohol, albeit at
high concentrations, perturbs NMDAR subunit composition in similar brain cultures (Snell
et al., 2001).
Examining signal transduction events potentially downstream of NMDAR and upstream of
hsp induction, the activity of PKC and changes in PKC isoform expression were determined
in HEC slices and/or cerebellar cultures during moderate alcohol exposure. Consistent with
ischemic preconditioning results (Uchiyama et al., 2003), PKC activity, moderately elevated
~15% after 2 d of alcohol, was increased ~40% after 6 d of exposure. Correlated with the
activity changes were relatively large increases (~200%) in PKCε levels along with modest
increases in PKCα and PKCδ (but not PKCβ) expression (Sivaswamy et al., 2008).
Furthermore, in alcohol-exposed cerebellar cells, focal adhesion kinase (FAK) and activated
p-FAK were modestly increased after 4 d and significantly higher after 6 d (Sivaswamy et
al., 2008), and transfection experiments using dominant negative FAK (“FRNK”) have
confirmed that FAK activation is upstream of hsp27 phosphorylation (S. Sivaswamy,
unpubl. results). FAK, a non-receptor tyrosine kinase activated by phosphorylation, has a
key role in transducing cytoskeletal-derived survival signals. Of importance, activation of
focal adhesion kinase (FAK) has been linked to cytoprotective elevations in hsp70 and
hsp27 (two hsps elevated by alcohol preconditioning) in severely stressed myocytes (Wei et
al., 2006). Overall, an emerging hypothesis is that alcohol (preconditioning)-induced
neuronal survival mechanisms involving hsp-dependent protection is intimately linked to
selective PKC and FAK activation, the focal adhesion complex, and stabilization of the
cytoskeleton.
CONCLUDING REMARKS
There is convincing evidence that light-moderate, non-binge alcohol intake reduces the risk
of coronary heart disease and, in agreement with an NIAAA position paper on moderate
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alcohol consumption (Gunzerath et al., 2004), that it does no apparent harm to cognition
during aging, even possibly reducing the risk of cognitive decline/dementia. The studies
reviewed here indicate that potential common anti-inflammatory mechanisms are initiated
by low-moderate alcohol levels and that these mechanisms have the capability of promoting
a cytoprotective state or condition. Notably, alcohol-related anti-inflammatory heat shock
protein and protein kinase changes in the brain bear similarities to those elucidated in heart,
particularly with respect to PKCε and quite likely other signal transduction kinases.
While alcohol levels achieved in periodic social consumption among older adults are no
doubt lower (albeit more prolonged) than those inducing neuroprotection in the brain
cultures summarized above, it is nonetheless conceivable that light-to-moderate, stable
alcohol ingestion over years exerts “preconditioning-like” effects on glia and neurons akin
to that which have been observed, leading to consequent dampening of the endogenous
neuroinflammatory processes associated with sometimes accelerated or “pathological” brain
aging (Chung et al., 2006). Further experimental studies are necessary to examine the
potential underlying mechanisms. In view of facts that cardiovascular disease and stroke are
two of the top three leading causes of mortality in developed countries and, according to a
Lancet review (Ferri et al., 2005), new cases of dementia are being diagnosed about every
seven seconds worldwide, it seems imperative that as much as possible is learned about the
apparent cytoprotective mechanisms engendered by low-moderate alcohol intake and levels.
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COX cyclooxygenase
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References
Abou-Agag LH, Khoo NK, Binsack R, White CR, Darley-Usmar V, Grenett HE, Booyse FM,
Digerness SB, Zhou F, Parks DA. Evidence of cardiovascular protection by moderate alcohol: role
of nitric oxide. Free Radic Biol Med 2005;39(4):540–8. [PubMed: 16043025]
Agarwal DP. Cardioprotective effects of light-moderate consumption of alcohol: a review of putative
mechanisms. Alcohol & Alcoholism 2002;37(5):409–15. [PubMed: 12217928]
Aggoun-Zouaoui D, Charriaut-Marlangue C, Rivera S, Jorquera I, Ben-Ari Y, Represa A, Aggoun-
Zouaoui D, Charriaut-Marlangue C, Rivera S, Jorquera I, Ben-Ari Y, Represa A. The HIV-1
envelope protein gp120 induces neuronal apoptosis in hippocampal slices. Neuroreport 1996;7(2):
433–6. [PubMed: 8730799]
Aikens ML, Grenett HE, Benza RL, Tabengwa EM, Davis GC, Booyse FM. Alcohol-induced
upregulation of plasminogen activators and fibrinolytic activity in cultured human endothelial cells.
Alcohol Clin Exp Res 1998;22(2):375–81. [PubMed: 9581643]
Al-Abed Y, Mitsuhashi T, Li H, Lawson JA, FitzGerald GA, Founds H, Donnelly T, Cerami A, Ulrich
P, Bucala R. Inhibition of advanced glycation endproduct formation by acetaldehyde: role in the
cardioprotective effect of ethanol. Proc Natl Acad Sci U S A 1999;96(5):2385–90. [PubMed:
10051651]
Albert MA, Glynn RJ, Ridker PM. Alcohol consumption and plasma concentration of C-reactive
protein. Circulation 2003;107(3):443–7. [PubMed: 12551869]
Baines CP, Song CX, Zheng YT, Wang GW, Zhang J, Wang OL, Guo Y, Bolli R, Cardwell EM, Ping
P. Protein kinase C epsilon interacts with and inhibits the permeability transition pore in cardiac
mitochondria. Circ Res 2003;92(8):873–80. [PubMed: 12663490]
Belmadani A, Kumar S, Schipma M, Collins MA, Neafsey EJ. Inhibition of amyloid-beta-induced
neurotoxicity and apoptosis by moderate ethanol preconditioning. Neuroreport 2004;15(13):2093–6.
[PubMed: 15486488]
Belmadani A, Neafsey EJ, Collins MA. Human immunodeficiency virus type 1 gp120 and ethanol
coexposure in rat organotypic brain slice cultures: Curtailment of gp120-induced neurotoxicity and
neurotoxic mediators by moderate but not high ethanol concentrations. J Neurovirol 2003;9(1):45–
54. [PubMed: 12587068]
Belmadani A, Zou JY, Schipma MJ, Neafsey EJ, Collins MA. Ethanol pre-exposure suppresses HIV-1
glycoprotein 120-induced neuronal degeneration by abrogating endogenous glutamate/Ca2+-
mediated neurotoxicity. Neuroscience 2001;104(3):769–81. [PubMed: 11440808]
Best N, Sundstrom LE, Mitchell J, Wheal HV. Pre-exposure to subtoxic levels prevents kainic acid
lesions in organotypic hippocampal slice cultures: effects of kainic acid on parvalbumin-
immunoreactive neurons and expression of heat shock protein 72 following the induction of
tolerance. Eur J Neurosci 1996;8(6):1209–19. [PubMed: 8752591]
Brenneman DE, Westbrook GL, Fitzgerald SP, Ennist DL, Elkins KL, Ruff MR, Pert CB, Brenneman
DE, Westbrook GL, Fitzgerald SP, Ennist DL, Elkins KL, Ruff MR, Pert CB. Neuronal cell killing
by the envelope protein of HIV and its prevention by vasoactive intestinal peptide. Nature
1988;335(6191):639–42. [PubMed: 2845276]
Brenner H, Rothenbacher D, Bode G, Marz W, Hoffmeister A, Koenig W. Coronary heart disease risk
reduction in a predominantly beer-drinking population. Epidemiology 2001;12(4):390–5.
[PubMed: 11416776]
Callemien D, Jerkovic V, Rozenberg R, Collin S. Hop as an interesting source of resveratrol for
brewers: optimization of the extraction and quantitative study by liquid chromatography/
atmospheric pressure chemical ionization tandem mass spectrometry. J Agric Food Chem
2005;53(2):424–9. [PubMed: 15656683]
Collins et al. Page 15
Alcohol Clin Exp Res. Author manuscript; available in PMC 2010 July 22.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Carmel JB, Kakinohana O, Mestril R, Young W, Marsala M, Hart RP. Mediators of ischemic
preconditioning identified by microarray analysis of rat spinal cord. Exp Neurol 2004;185(1):81–
96. [PubMed: 14697320]
Cebere A, Liljequist S. Ethanol differentially inhibits homoquinolinic acid- and NMDA-induced
neurotoxicity in primary cultures of cerebellar granule cells. Neurochem Res 2003;28(8):1193–9.
[PubMed: 12834259]
Chandler LJ, Sumners C, Crews FT. Ethanol inhibits NMDA receptor-mediated excitotoxicity in rat
primary neuronal cultures. Alcohol Clin Exp Res 1993;17(1):54–60. [PubMed: 8383926]
Chen CH, Gray MO, Mochly-Rosen D. Cardioprotection from ischemia by a brief exposure to
physiological levels of ethanol: role of epsilon protein kinase C. Proc Natl Acad Sci U S A
1999;96(22):12784–9. [PubMed: 10536000]
Chen Y, Davis-Gorman G, Watson RR, McDonagh PF. Chronic ethanol consumption modulates
myocardial ischaemia-reperfusion injury in murine AIDS. Alcohol & Alcoholism 2003;38(1):18–
24. [PubMed: 12554602]
Chopp M, Chen H, Ho KL, Dereski MO, Brown E, Hetzel FW, Welch KM, Chopp M, Chen H, Ho
KL, Dereski MO, Brown E, Hetzel FW, Welch KM. Transient hyperthermia protects against
subsequent forebrain ischemic cell damage in the rat. Neurology 1989;39(10):1396–8. [PubMed:
2797463]
Chung HY, Sung B, Jung KJ, Zou Y, Yu BP. The molecular inflammatory process in aging.
Antioxidants & Redox Signaling 2006;8(3–4):572–81. [PubMed: 16677101]
Cleophas TJ. Wine, beer and spirits and the risk of myocardial infarction: a systematic review. Biomed
Pharmacother 1999;53(9):417–23. [PubMed: 10554677]
Cohen G, Heikkila RE, Allis B, Cabbat F, Dembiec D, MacNamee D, Mytilineou C, Winston B.
Destruction of sympathetic nerve terminals by 6-hydroxydopamine: protection by 1-phenyl-3-(2-
thiazolyl)-2-thiourea, diethyldithiocarbamate, methimazole, cysteamine, ethanol and n-butanol. J
Pharmacol Exp Ther 1976;199(2):336–52. [PubMed: 185360]
Collins MA, Neafsey EJ, Zou JY. HIV-1 gp120 neurotoxicity in brain cultures is prevented by
moderate ethanol pretreatment. Neuroreport 2000;11(6):1219–22. [PubMed: 10817595]
Corrao G, Rubbiati L, Bagnardi V, Zambon A, Poikolainen K. Alcohol and coronary heart disease: a
meta-analysis. Addiction 2000;95(10):1505–23. [PubMed: 11070527]
Das DK, Maulik N. Resveratrol in cardioprotection: a therapeutic promise of alternative medicine.
Molecular Interventions 2006;6(1):36–47. [PubMed: 16507749]
Das DK, Ursini F. Alcohol and wine in health and disease. Ann N Y Acad Sci 2002;957:1–350.
[PubMed: 12074956]
Das S, Khan N, Mukherjee S, Bagchi D, Gurusamy N, Swartz H, Das DK. Redox regulation of
resveratrol-mediated switching of death signal into survival signal. Free Radic Biol Med
2008;44(1):82–90. [PubMed: 18045550]
Das SK, Vasudevan DM. Alcohol-induced oxidative stress. Life Sci 2007;81(3):177–87. [PubMed:
17570440]
Davies MJ, Baer DJ, Judd JT, Brown ED, Campbell WS, Taylor PR. Effects of moderate alcohol
intake on fasting insulin and glucose concentrations and insulin sensitivity in postmenopausal
women: a randomized controlled trial. JAMA 2002;287(19):2559–62. [PubMed: 12020337]
Dayton C, Yamaguchi T, Kamada K, Carter P, Korthuis RJ. Antecedent ethanol ingestion prevents
postischemic leukocyte adhesion and P-selectin expression by a protein kinase C-dependent
mechanism. Dig Dis Sci 2005;50(4):684–90. [PubMed: 15844702]
Dirnagl U, Simon RP, Hallenbeck JM. Ischemic tolerance and endogenous neuroprotection. Trends
Neurosci 2003;26(5):248–54. [PubMed: 12744841]
Djousse L, Ellison RC, Beiser A, Scaramucci A, D’Agostino RB, Wolf PA. Alcohol consumption and
risk of ischemic stroke: The Framingham Study. Stroke 2002;33(4):907–12. [PubMed: 11935035]
Doll R. One for the heart. BMJ 1997;315(7123):1664–8. [PubMed: 9448535]
Dufouil C, Tzourio C, Brayne C, Berr C, Amouyel P, Alperovitch A. Influence of apolipoprotein E
genotype on the risk of cognitive deterioration in moderate drinkers and smokers. Epidemiology
2000;11(3):280–4. [PubMed: 10784244]
Collins et al. Page 16
Alcohol Clin Exp Res. Author manuscript; available in PMC 2010 July 22.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H,
Huang Y, Jorm A, Mathers C, Menezes PR, Rimmer E, Scazufca M. Global prevalence of
dementia: a Delphi consensus study. Lancet 2005;366(9503):2112–7. [PubMed: 16360788]
Freiberg MS, Samet JH. Alcohol and coronary heart disease: the answer awaits a randomized
controlled trial. Circulation 2005;112(10):1379–81. [PubMed: 16145011]
Gaskin FS, Kamada K, Yusof M, Korthuis RJ. 5′-AMP-activated protein kinase activation prevents
postischemic leukocyte-endothelial cell adhesive interactions. American Journal of Physiology -
Heart & Circulatory Physiology 2007;292(1):H326–32. [PubMed: 16935999]
Gaziano JM, Hennekens CH, Godfried SL, Sesso HD, Glynn RJ, Breslow JL, Buring JE. Type of
alcoholic beverage and risk of myocardial infarction. Am J Cardiol 1999;83(1):52–7. [PubMed:
10073785]
Gidday JM. Cerebral preconditioning and ischaemic tolerance. Nature Reviews Neuroscience
2006;7(6):437–48.
Gray MO, Zhou HZ, Schafhalter-Zoppoth I, Zhu P, Mochly-Rosen D, Messing RO. Preservation of
base-line hemodynamic function and loss of inducible cardioprotection in adult mice lacking
protein kinase C epsilon. J Biol Chem 2004;279(5):3596–604. [PubMed: 14600145]
Gunzerath L, Faden V, Zakhari S, Warren K. National Institute on Alcohol Abuse and Alcoholism
report on moderate drinking. Alcohol Clin Exp Res 2004;28(6):829–47. [PubMed: 15201626]
Hillbom M, Haapaniemi H, Juvela S, Palomaki H, Numminen H, Kaste M. Recent alcohol
consumption, cigarette smoking, and cerebral infarction in young adults. Stroke 1995;26(1):40–5.
[PubMed: 7839395]
Juric D, Wojciechowski P, Das DK, Netticadan T. Prevention of concentric hypertrophy and diastolic
impairment in aortic-banded rats treated with resveratrol. American Journal of Physiology - Heart
& Circulatory Physiology 2007;292(5):H2138–43. [PubMed: 17488730]
Kamada K, Dayton CB, Yamaguchi T, Korthuis RJ. Antecedent ethanol ingestion prevents
postischemic microvascular dysfunction. Pathophysiology 2004;10(2):131–7. [PubMed:
15006419]
Kanai AJ, Mesaros S, Finkel MS, Oddis CV, Birder LA, Malinski T. Beta-adrenergic regulation of
constitutive nitric oxide synthase in cardiac myocytes. Am J Physiol 1997;273(4 Pt 1):C1371–7.
[PubMed: 9357783]
Kanno S, Lee PC, Zhang Y, Ho C, Griffith BP, Shears LL 2nd, Billiar TR. Attenuation of myocardial
ischemia/reperfusion injury by superinduction of inducible nitric oxide synthase. Circulation
2000;101(23):2742–8. [PubMed: 10851213]
Kaul M, Lipton SA. Mechanisms of neuronal injury and death in HIV-1 associated dementia. Current
HIV Research 2006;4(3):307–18. [PubMed: 16842083]
Khadour FH, O’Brien DW, Fu Y, Armstrong PW, Schulz R. Endothelial nitric oxide synthase
increases in left atria of dogs with pacing-induced heart failure. Am J Physiol 1998;275(6 Pt
2):H1971–8. [PubMed: 9843795]
Kitagawa K, Matsumoto M, Tagaya M, Hata R, Ueda H, Niinobe M, Handa N, Fukunaga R, Kimura
K, Mikoshiba K, et al. ‘Ischemic tolerance’ phenomenon found in the brain. Brain Res
1990;528(1):21–4. [PubMed: 2245337]
Kitakaze M, Node K, Minamino T, Kosaka H, Shinozaki Y, Mori H, Inoue M, Hori M, Kamada T.
Role of nitric oxide in regulation of coronary blood flow during myocardial ischemia in dogs. J
Am Coll Cardiol 1996;27(7):1804–12. [PubMed: 8636571]
Klatsky AL. Alcohol, coronary disease, and hypertension. Annu Rev Med 1996;47:149–60. [PubMed:
8712769]
Klatsky AL, Friedman GD, Siegelaub AB. Alcohol consumption before myocardial infarction. Results
from the Kaiser-Permanente epidemiologic study of myocardial infarction. Ann Intern Med
1974;81:294–301. [PubMed: 4850474]
Kojda G, Kottenberg K. Regulation of basal myocardial function by NO. Cardiovasc Res 1999;41(3):
514–23. [PubMed: 10435023]
Korthuis RJ. Alcohol and cardioprotection. Pathophysiology 2004;10(2):1–145.
Korthuis, RJ. Antecedent ethanol ingestion prevents postischemic microvascular dysfunction. In:
Shepro, D., editor. Microvascular Research: Biology and Pathology. 2006. p. 777-782.
Collins et al. Page 17
Alcohol Clin Exp Res. Author manuscript; available in PMC 2010 July 22.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Krenz M, Cohen MV, Downey JM. Protective and anti-protective effects of acute ethanol exposure in
myocardial ischemia/reperfusion. Pathophysiology 2004;10(2):113–9. [PubMed: 15006417]
Kuller LH, Lopez OL, Newman A, Beauchamp NJ, Burke G, Dulberg C, Fitzpatrick A, Fried L, Haan
MN. Risk factors for dementia in the cardiovascular health cognition study. Neuroepidemiology
2003;22(1):13–22. [PubMed: 12566949]
Lamas S, Perez-Sala D, Moncada S. Nitric oxide: from discovery to the clinic. Trends Pharmacol Sci
1998;19(11):436–8. [PubMed: 9850605]
Larrieu S, Letenneur L, Helmer C, Dartigues JF, Barberger-Gateau P. Nutritional factors and risk of
incident dementia in the PAQUID longitudinal cohort. J Nutr Health Aging 2004;8(3):150–4.
[PubMed: 15129300]
Leak RK, Liou AK, Zigmond MJ. Effect of sublethal 6-hydroxydopamine on the response to
subsequent oxidative stress in dopaminergic cells: evidence for preconditioning. J Neurochem
2006;99(4):1151–63. [PubMed: 16956375]
Lekli I, Szabo G, Juhasz B, Das S, Das M, Varga E, Szendrei L, Gesztelyi R, Varadi J, Bak I, Das DK,
Tosaki A. Protective mechanisms of resveratrol against ischemia-reperfusion-induced damage in
hearts obtained from Zucker obese rats: the role of GLUT-4 and endothelin. American Journal of
Physiology - Heart & Circulatory Physiology 2008;294(2):H859–66. [PubMed: 18065527]
Liao SL, Chen WY, Raung SL, Chen CJ. Ethanol attenuates ischemic and hypoxic injury in rat brain
and cultured neurons. Neuroreport 2003;14(16):2089–94. [PubMed: 14600503]
Loke KE, McConnell PI, Tuzman JM, Shesely EG, Smith CJ, Stackpole CJ, Thompson CI, Kaley G,
Wolin MS, Hintze TH. Endogenous endothelial nitric oxide synthase-derived nitric oxide is a
physiological regulator of myocardial oxygen consumption. Circ Res 1999;84(7):840–5. [PubMed:
10205152]
Lucas DL, Brown RA, Wassef M, Giles TD. Alcohol and the cardiovascular system research
challenges and opportunities. J Am Coll Cardiol 2005;45(12):1916–24. [PubMed: 15963387]
Luchsinger JA, Tang MX, Siddiqui M, Shea S, Mayeux R. Alcohol intake and risk of dementia. J Am
Geriatr Soc 2004;52(4):540–6. [PubMed: 15066068]
Maclure M. Demonstration of deductive meta-analysis: ethanol intake and risk of myocardial
infarction. Epidemiol Rev 1993;15(2):328–51. [PubMed: 8174661]
Marfella R, Cacciapuoti F, Siniscalchi M, Sasso FC, Marchese F, Cinone F, Musacchio E, Marfella
MA, Ruggiero L, Chiorazzo G, Liberti D, Chiorazzo G, Nicoletti GF, Saron C, D’Andrea F,
Ammendola C, Verza M, Coppola L. Effect of moderate red wine intake on cardiac prognosis after
recent acute myocardial infarction of subjects with Type 2 diabetes mellitus. Diabet Med
2006;23(9):974–81. [PubMed: 16922703]
McConnell MV, Vavouranakis I, Wu LL, Vaughan DE, Ridker PM. Effects of a single, daily alcoholic
beverage on lipid and hemostatic markers of cardiovascular risk. Am J Cardiol 1997;80(9):1226–
8. [PubMed: 9359559]
Mehlig K, Skoog I, Guo X, Schutze M, Gustafson D, Waern M, Ostling S, Bjorkelund C, Lissner L.
Alcoholic beverages and incidence of dementia: 34-year follow-up of the prospective population
study of women in Goteborg. Am J Epidemiol 2008;167(6):684–91. [PubMed: 18222934]
Mitchell RM, Neafsey EJ, Collins MA. Neuroprotection by moderate ethanol preconditioning:
Involvement of NMDA receptor signaling. Alcohol Clin Exp Res 2007;31(s2):196A.
Miyamae M, Diamond I, Weiner MW, Camacho SA, Figueredo VM. Regular alcohol consumption
mimics cardiac preconditioning by protecting against ischemia-reperfusion injury. Proc Natl Acad
Sci U S A 1997;94(7):3235–9. [PubMed: 9096376]
Mokni M, Limam F, Elkahoui S, Amri M, Aouani E. Strong cardioprotective effect of resveratrol, a
red wine polyphenol, on isolated rat hearts after ischemia/reperfusion injury. Arch Biochem
Biophys 2007;457(1):1–6. [PubMed: 17125727]
Mukamal KJ, Ascherio A, Mittleman MA, Conigrave KM, Camargo CA Jr, Kawachi I, Stampfer MJ,
Willett WC, Rimm EB. Alcohol and risk for ischemic stroke in men: the role of drinking patterns
and usual beverage. Ann Intern Med 2005a;142(1):11–9. [PubMed: 15630105]
Mukamal KJ, Chung H, Jenny NS, Kuller LH, Longstreth WT Jr, Mittleman MA, Burke GL, Cushman
M, Beauchamp NJ Jr, Siscovick DS. Alcohol use and risk of ischemic stroke among older adults:
the cardiovascular health study. Stroke 2005b;36(9):1830–4. [PubMed: 16081863]
Collins et al. Page 18
Alcohol Clin Exp Res. Author manuscript; available in PMC 2010 July 22.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Mukamal KJ, Chung H, Jenny NS, Kuller LH, Longstreth WT Jr, Mittleman MA, Burke GL, Cushman
M, Psaty BM, Siscovick DS. Alcohol consumption and risk of coronary heart disease in older
adults: the Cardiovascular Health Study. J Am Geriatr Soc 2006;54(1):30–7. [PubMed: 16420195]
Mukamal KJ, Conigrave KM, Mittleman MA, Camargo CA Jr, Stampfer MJ, Willett WC, Rimm EB.
Roles of drinking pattern and type of alcohol consumed in coronary heart disease in men. N Engl J
Med 2003a;348(2):109–18. [PubMed: 12519921]
Mukamal KJ, Jensen MK, Gronbaek M, Stampfer MJ, Manson JE, Pischon T, Rimm EB. Drinking
frequency, mediating biomarkers, and risk of myocardial infarction in women and men.
Circulation 2005c;112(10):1406–13. [PubMed: 16129796]
Mukamal KJ, Jensen MK, Gronbaek M, Stampfer MJ, Manson JE, Pischon T, Rimm EB. Drinking
frequency, mediating biomarkers, and risk of myocardial infarction in women and men.
Circulation 2005d;112(10):1406–13. [PubMed: 16129796]
Mukamal KJ, Kuller LH, Fitzpatrick AL, Longstreth WT Jr, Mittleman MA, Siscovick DS.
Prospective study of alcohol consumption and risk of dementia in older adults. JAMA 2003b;
289(11):1405–13. [PubMed: 12636463]
Mukamal KJ, Longstreth WT Jr, Mittleman MA, Crum RM, Siscovick DS. Alcohol consumption and
subclinical findings on magnetic resonance imaging of the brain in older adults: the cardiovascular
health study. Stroke 2001;32(9):1939–46. [PubMed: 11546878]
Mukamal KJ, Muller JE, Maclure M, Sherwood JB, Mittleman MA. Lack of effect of recent alcohol
consumption on the course of acute myocardial infarction. Am Heart J 1999;138(5 Pt 1):926–33.
[PubMed: 10539825]
Nvue R, Gorianov V, Best N, Sundstrom LE, Pringle AK. Time window and pharmacological
characterisation of kainate-mediated preconditioning in organotypic rat hippocampal slice cultures.
Neurosci Lett 2004;367(3):365–8. [PubMed: 15337267]
Okubo T, Suto N, Kudo S, Hanada H, Mikuniya A, Okumura K. A study on the effects of endogenous
nitric oxide on coronary blood flow, myocardial oxygen extraction and cardiac contractility.
Fundam Clin Pharmacol 1999;13(1):34–42. [PubMed: 10027086]
Orgogozo JM, Dartigues JF, Lafont S, Letenneur L, Commenges D, Salamon R, Renaud S, Breteler
MB. Wine consumption and dementia in the elderly: a prospective community study in the
Bordeaux area. Rev Neurol (Paris) 1997;153(3):185–92. [PubMed: 9296132]
Pagel PS, Krolikowski JG, Kehl F, Mraovic B, Kersten JR, Warltier DC. The role of mitochondrial
and sarcolemmal K(ATP) channels in canine ethanol-induced preconditioning in vivo. Anesth
Analg 2002;94(4):841–8. [PubMed: 11916782]
Patel RP, McAndrew J, Sellak H, White CR, Jo H, Freeman BA, Darley-Usmar VM. Biological
aspects of reactive nitrogen species. Biochim Biophys Acta 1999;1411(2–3):385–400. [PubMed:
10320671]
Pinder RM, Sandler M. Alcohol, wine and mental health: focus on dementia and stroke. J
Psychopharmacol (Oxf) 2004;18(4):449–56.
Ping P, Zhang J, Pierce WM Jr, Bolli R. Functional proteomic analysis of protein kinase C epsilon
signaling complexes in the normal heart and during cardioprotection. Circ Res 2001;88(1):59–62.
[PubMed: 11139474]
Radomski MW, Moncada S. Regulation of vascular homeostasis by nitric oxide. Thromb Haemost
1993;70(1):36–41. [PubMed: 7694388]
Renaud SC, Ruf JC. Effects of alcohol on platelet functions. Clin Chim Acta 1996;246(1–2):77–89.
[PubMed: 8814972]
Reynolds K, Lewis B, Nolen JD, Kinney GL, Sathya B, He J. Alcohol consumption and risk of stroke:
a meta-analysis. JAMA 2003;289(5):579–88. [PubMed: 12578491]
Ridker PM, Vaughan DE, Stampfer MJ, Glynn RJ, Hennekens CH. Association of moderate alcohol
consumption and plasma concentration of endogenous tissue-type plasminogen activator. JAMA
1994;272(12):929–33. [PubMed: 7794308]
Rimm EB, Williams P, Fosher K, Criqui M, Stampfer MJ. Moderate alcohol intake and lower risk of
coronary heart disease: meta-analysis of effects on lipids and haemostatic factors. BMJ
1999;319(7224):1523–8. [PubMed: 10591709]
Collins et al. Page 19
Alcohol Clin Exp Res. Author manuscript; available in PMC 2010 July 22.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362(6423):801–
9. [PubMed: 8479518]
Ruitenberg A, van Swieten JC, Witteman JC, Mehta KM, van Duijn CM, Hofman A, Breteler MM.
Alcohol consumption and risk of dementia: the Rotterdam Study. Lancet 2002;359(9303):281–6.
[PubMed: 11830193]
Sato M, Fraga C, Das DK. Induction of the expression of cardioprotective proteins after mild-to-
moderate consumption of alcohol. Pathophysiology 2004;10(2):139–45. [PubMed: 15006420]
Shigematsu S, Ishida S, Hara M, Takahashi N, Yoshimatsu H, Sakata T, Korthuis RJ. Resveratrol, a
red wine constituent polyphenol, prevents superoxide-dependent inflammatory responses induced
by ischemia/reperfusion, platelet-activating factor, or oxidants. Free Radic Biol Med 2003;34(7):
810–7. [PubMed: 12654468]
Sierksma A, van der Gaag MS, Kluft C, Hendriks HF. Moderate alcohol consumption reduces plasma
C-reactive protein and fibrinogen levels; a randomized, diet-controlled intervention study. Eur J
Clin Nutr 2002a;56(11):1130–6. [PubMed: 12428180]
Sierksma A, van der Gaag MS, Kluft C, Hendriks HF. Moderate alcohol consumption reduces plasma
C-reactive protein and fibrinogen levels; a randomized, diet-controlled intervention study. Eur J
Clin Nutr 2002b;56(11):1130–6. [PubMed: 12428180]
Singh AK, Jiang Y, Gupta S, Benlhabib E. Effects of chronic ethanol drinking on the blood brain
barrier and ensuing neuronal toxicity in alcohol-preferring rats subjected to intraperitoneal LPS
injection. Alcohol & Alcoholism 2007;42(5):385–99. [PubMed: 17341516]
Sivaswamy S, Neafsey EJ, Collins MA. PKC and Focal Adhesion Kinase (FAK): Possible Transducer
Roles in Ethanol Preconditioning-Induced Neuroprotection from HIV-1 gp120. J Neurochem
2008;104(Suppl 1):32.
Snell LD, Bhave SV, Tabakoff B, Hoffman PL, Snell LD, Bhave SV, Tabakoff B, Hoffman PL.
Chronic ethanol exposure delays the ‘developmental switch’ of the NMDA receptor 2A and 2B
subunits in cultured cerebellar granule neurons. J Neurochem 2001;78(2):396–405. [PubMed:
11461975]
Stampfer MJ, Kang JH, Chen J, Cherry R, Grodstein F. Effects of moderate alcohol consumption on
cognitive function in women. N Engl J Med 2005;352(3):245–53. [PubMed: 15659724]
Sumeray MS, Rees DD, Yellon DM. Infarct size and nitric oxide synthase in murine myocardium. J
Mol Cell Cardiol 2000;32(1):35–42. [PubMed: 10652188]
Thun MJ, Peto R, Lopez AD, Monaco JH, Henley SJ, Heath CW Jr, Doll R. Alcohol consumption and
mortality among middle-aged and elderly U.S. adults. N Engl J Med 1997;337(24):1705–14.
[PubMed: 9392695]
Truelsen T, Thudium D, Gronbaek M. Amount and type of alcohol and risk of dementia: the
Copenhagen City Heart Study. Neurology 2002;59(9):1313–9. [PubMed: 12427876]
Tsai SK, Hung LM, Fu YT, Cheng H, Nien MW, Liu HY, Zhang FB, Huang SS. Resveratrol
neuroprotective effects during focal cerebral ischemia injury via nitric oxide mechanism in rats. J
Vasc Surg 2007;46(2):346–53. [PubMed: 17600658]
Uchiyama Y, Otani H, Wakeno M, Okada T, Uchiyama T, Sumida T, Kido M, Imamura H, Nakao S,
Shingu K. Role of mitochondrial KATP channels and protein kinase C in ischaemic
preconditioning. Clin Exp Pharmacol Physiol 2003;30(5–6):426–36. [PubMed: 12859437]
Wallerath T, Poleo D, Li H, Forstermann U. Red wine increases the expression of human endothelial
nitric oxide synthase: a mechanism that may contribute to its beneficial cardiovascular effects. J
Am Coll Cardiol 2003;41(3):471–8. [PubMed: 12575978]
Wang Q, Sun AY, Simonyi A, Kalogeris TJ, Miller DK, Sun GY, Korthuis RJ. Ethanol
preconditioning protects against ischemia/reperfusion-induced brain damage: role of NADPH
oxidase-derived ROS. Free Radic Biol Med 2007;43(7):1048–60. [PubMed: 17761301]
Wegelius K, Korpi ER. Ethanol inhibits NMDA-induced toxicity and trophism in cultured cerebellar
granule cells. Acta Physiol Scand 1995;154(1):25–34. [PubMed: 7572199]
Wei H, Campbell W, Vander Heide RS. Heat shock-induced cardioprotection activates cytoskeletal-
based cell survival pathways. American Journal of Physiology - Heart & Circulatory Physiology
2006;291(2):H638–47. [PubMed: 16565316]
Collins et al. Page 20
Alcohol Clin Exp Res. Author manuscript; available in PMC 2010 July 22.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Yamaguchi T, Dayton C, Shigematsu T, Carter P, Yoshikawa T, Gute DC, Korthuis RJ.
Preconditioning with ethanol prevents postischemic leukocyte-endothelial cell adhesive
interactions. American Journal of Physiology - Heart & Circulatory Physiology
2002;283(3):H1019–30. [PubMed: 12181132]
Yamaguchi T, Dayton CB, Ross CR, Yoshikawa T, Gute DC, Korthuis RJ. Late preconditioning by
ethanol is initiated via an oxidant-dependent signaling pathway. Free Radic Biol Med
2003;34(3):365–76. [PubMed: 12543252]
Yamaguchi T, Kamada K, Dayton C, Gaskin FS, Yusof M, Yoshikawa T, Carter P, Korthuis RJ. Role
of eNOS-derived NO in the postischemic anti-inflammatory effects of antecedent ethanol
ingestion in murine small intestine. American Journal of Physiology - Heart & Circulatory
Physiology 2007;292(3):H1435–42. [PubMed: 17098834]
Yuan JM, Ross RK, Gao YT, Henderson BE, Yu MC. Follow up study of moderate alcohol intake and
mortality among middle aged men in Shanghai, China. BMJ 1997;314:18–23. [PubMed:
9001474]
Zakhari S. Molecular mechanisms underlying alcohol-induced cardioprotection: contribution of
hemostatic components. Introduction to the symposium. Alcohol Clin Exp Res 1999;23(6):1108–
10. [PubMed: 10397298]
Zeiher AM, Drexler H, Saurbier B, Just H. Endothelium-mediated coronary blood flow modulation in
humans. Effects of age, atherosclerosis, hypercholesterolemia, and hypertension. J Clin Invest
1993;92(2):652–62. [PubMed: 8349804]
Zhou HZ, Karliner JS, Gray MO. Moderate alcohol consumption induces sustained cardiac protection
by activating PKC-epsilon and Akt. American Journal of Physiology - Heart & Circulatory
Physiology 2002;283(1):H165–74. [PubMed: 12063287]
Zhou HZ, Ma X, Cecchini G, Simonis U, Gray MO. Moderate ethanol consumption improves
mitochondrial function and cardiac energetics during oxidative stress: roles of PKCepsilon and
Akt. Circulation 2004;110(17):III–203.
Zhu P, Zhou HZ, Gray MO. Chronic ethanol-induced myocardial protection requires activation of
mitochondrial K(ATP) channels. J Mol Cell Cardiol 2000;32(11):2091–5. [PubMed: 11040112]
Collins et al. Page 21
Alcohol Clin Exp Res. Author manuscript; available in PMC 2010 July 22.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 1. The relationships of alcohol intake with risks of coronary heart disease, ischemic
stroke, and dementia among participants in the Cardiovascular Health Study
Long-term abstainers were the reference category. The Y-axis indicates hazard ratios for
coronary heart disease and ischemic stroke, and odds ratios for dementia. See text for
appropriate references.
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Figure 2. Moderate drinking and mitochondrial protein kinase Cε localization
Adult male C57BL/6 mice were fed 10% alcohol (vol/vol) in drinking water for 12 weeks as
described (Zhou et al., 2004). Mitochondrial fractions were prepared from isolated hearts by
differential centrifugation. (A) Western blot analysis of mitochondrial fractions from
normoxic hearts. Moderate alcohol intake had no significant effects on mitochondrial
protein kinase Cε expression. (B) Alcohol consumption produced a 3-fold increase in
mitochondrial protein kinase Cε in hearts following 25 min ischemia and 30 min reperfusion
on a Langendorff apparatus.
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Figure 3. Protein kinase Cε is a key factor in alcohol-mediated cardioprotection
Submitochondrial particles were prepared as described (Zhou et al., 2004) from hearts of
alcohol-fed (black bars) and control (white bars) mice and used to measure respiratory chain
complex activities after ischemia-reperfusion. (A) Moderate alcohol intake significantly
improved mitochondrial NADH-oxidase activity after stress. In contrast, sustained
cardioprotection was blocked by a protein kinase Cε antagonist peptide and in knockout
mice. (B) Chronic protection against NADH-Q1 reductase (Complex I) injury was also
abolished by protein kinase C inhibition. n = 6 hearts per condition. *P<0.05 vs. control
ischemia-reperfusion hearts.
Collins et al. Page 24
Alcohol Clin Exp Res. Author manuscript; available in PMC 2010 July 22.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Collins et al. Page 25
Alcohol Clin Exp Res. Author manuscript; available in PMC 2010 July 22.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 4.
A. Cardioprotective and molecular targets of alcohol.Cardioprotective targets are shown
on the right whereas the molecular targets are shown on the left.
B. Cardioprotective and molecular targets of resveratrol. Cardioprotective targets are
shown on the right whereas the molecular targets are shown on the left.
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